Ireland
--:--IST
Starting soon Phase 4

Effect of Oxybutynin on Opioid Use After Urologic Surgery in Children

NCT07911137 · tracked via the Priya Life Science Canada tracker
Phase
Phase 4
Started
2026-11-01
Last updated
2026-11-02

Condition(s) studied

Ureteropelvic Junction ObstructionHypospadias

Investigational drug(s) / intervention(s)

Oxybutynin →Placebo

Oxybutynin: Participants will receive oxybutynin 0.2 mg/kg (to a maximum dose of 5 mg), orally administered by the day surgery nurse in the day surgery holding area prior to surgery.

Placebo: Participants will receive a matching placebo tablet, orally administered by the day surgery nurse in the day surgery holding area prior to surgery.

Study summary

The goal of this clinical trial is to determine whether giving oxybutynin before urologic reconstruction surgery reduces the amount of opioid pain medication needed in children. Oxybutynin is a medication that helps reduce bladder spasms, which can cause pain and discomfort after surgery.

The main question this study aims to answer is:

Does giving oxybutynin before surgery reduce the amount of opioid pain medication children need during the first 6 hours after surgery?

Researchers will compare oxybutynin with a placebo (a tablet containing no active medication) to see whether oxybutynin reduces opioid use after surgery.

Eligibility

Sex
ALL
Min age
—
Max age
17 Years
Healthy volunteers
No
Inclusion Criteria: * All children aged 0 to 17 years old admitted for pyeloplasty or hypospadias repair. There is no minimum weight for inclusion Exclusion Criteria: * Contraindications to anticholinergic medications * Urinary retention disorders * Gastrointestinal obstruction/ileus * Contraindications to anesthetic protocol, including 1) allergy to any anesthetic medication in protocol, 2) refusal of regional technique, 3) contraindications to ketorolac (i.e., recent GI bleed, recent intracranial bleed, renal dysfunction, acute kidney injury)

Primary outcome measure(s)

  • Total Cumulative Postoperative Opioid Consumption (MME/kg) — From the end of surgery through 6 hours postoperatively
    Total cumulative morphine milligram equivalents per kilogram (MME/kg) administered within 6 hours after surgery

Trial sites (1)

FacilityCityRegionStatus
Alberta Children's Hospital Calgary Alberta

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07911137 on ClinicalTrials.gov ↗ ← All trials in Canada